Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Virchows Arch ; 432(3): 299-300, 1998 Mar.
Article in English | MEDLINE | ID: mdl-9532011

ABSTRACT

This case report describes a chondroma of the bladder in a 63-year-old woman with clinical complaints of pain in the left fossa iliaca. The lesion was a tumour with a lobulated growth pattern composed of chondrocytes embedded in a chondroid matrix. Neither mitotic figures nor increased cellularity were present. Nuclei were inconspicuous. Immunohistochemical examination showed reactivity for S100 and vimentin.


Subject(s)
Chondroma/pathology , Urinary Bladder Neoplasms/pathology , Biomarkers, Tumor/analysis , Female , Humans , Ki-67 Antigen/analysis , Middle Aged , Tumor Suppressor Protein p53/analysis
2.
Pathol Res Pract ; 183(3): 271-6, 1988 Jun.
Article in English | MEDLINE | ID: mdl-2843840

ABSTRACT

In order to evaluate a possible transition from proliferative lesions of the breast to ductal carcinoma in situ (DCIS), an immunohistochemical retrospective analysis was carried out. Twelve patients with hyperplasia without atypia, 11 patients with hyperplastic lesions with atypia, 21 patients with DCIS and 24 patients with invasive carcinoma were studied. The expression of carcino-embryonic antigen (CEA), a dedifferentiation marker, was investigated, applying one monoclonal antibody (Amersham). The expression of human milk fat globulin (HMFG), a differentiation marker, was studied by means of three monoclonal antibodies. The results reveal that no CEA activity can be demonstrated in normal and hyperplastic breast tissue, either with or without atypia. The monoclonal antibody was positive in 48% of DCIS and 50% of the invasive carcinomas. We failed to observe a correlation between the presence of CEA and the differentiation of the tumor. The application of this antiserum adds no substantial information about the phenotypic alterations during the progression from atypical hyperplasia to DCIS. HMFG was present in benign as well as in malignant breast lesions. Therefore, we conclude that HMFG is not useful for the evaluation of the phenotypic change from atypical hyperplasia to malignancy. However, as pointed out by others, it can be used in a diagnostic panel of different antibodies in the distinction between epithelial and non-epithelial lesions.


Subject(s)
Breast Neoplasms/analysis , Breast/analysis , Carcinoembryonic Antigen/analysis , Carcinoma in Situ/analysis , Membrane Glycoproteins/analysis , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal , Breast/immunology , Breast/pathology , Breast Neoplasms/immunology , Carcinoma in Situ/immunology , Carcinoma, Intraductal, Noninfiltrating/analysis , Carcinoma, Intraductal, Noninfiltrating/immunology , Female , Humans , Hyperplasia , Middle Aged , Mucin-1 , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...